M&A
Lonza agrees to buy 5 Merck KGaA US manufacturing facilities for ADC and viral vector production
Key Facts
Signal Type
M&A
Industry
Biotech
Companies
Lonza, Merck KGaA, William Blair, Roche, Samsung Biologics
Date
November 3, 2026
Lonza has agreed to buy five Merck KGaA US manufacturing facilities in a deal valued at approximately CHF 350 million. The sites cover bioconjugation (St. Louis, MO), high-potency payload-linkers (Madison and Verona, WI), viral vectors (Carlsbad, CA), and aseptic fill-finish (Indianapolis, IN).
About 1,100 employees will transfer to Lonza as part of the acquisition. Lonza expects the deal to close in mid-2027 and projects the acquired facilities to contribute roughly CHF 250 million in sales by 2028.
The acquisition directly impacts the ~1,100 transferring employees, who will need to be integrated into Lonza's systems and culture. It also affects current and prospective customers of these five plants, as Lonza plans to broaden the customer pipeline and increase capacity utilization.
Lonza's existing US operations — now expanding to nine sites with over 6,000 employees — will see changes in how ADC and viral vector services are delivered across both US and European (Visp, Switzerland) locations.
Lonza strengthens its position in high-growth modalities, particularly ADCs and viral vectors, at a time when the global bioconjugation market is projected to grow from $30 billion to $110 billion by 2033.
Watch for integration milestones between now and mid-2027, including IT, HR, and operational systems consolidation across the five sites. Also monitor how quickly Lonza can raise capacity utilization and bring margins in line with its existing business by the mid-2030s.
Industry watchers should also track whether Lonza announces additional acquisitions while integrating these plants, as the CEO explicitly signaled readiness for parallel deal-making.
Source:
BioSpaceGet biotech signals in your CRM
FDA approvals and rejections, clinical trial results, pharma M&A, drug recalls, and funding rounds.
